The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCluskie, M. J.
Right arrow Articles by Davis, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCluskie, M. J.
Right arrow Articles by Davis, H. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Hepatitis B
The Journal of Immunology, 1998, 161: 4463-4466.
Copyright © 1998 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: CpG DNA Is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice1

Michael J. McCluskie*,{dagger} and Heather L. Davis2,*,{dagger},{ddagger}

* Loeb Research Institute, Ottawa, Canada; {dagger} Departments of Cellular and Molecular Medicine and {ddagger} Microbiology, Immunology, and Biochemistry, Faculty of Medicine, and § School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada

Mucosal immunity is difficult to induce with subunit vaccines unless such vaccines are administered with a mucosal adjuvant such as cholera toxin (CT); however, CT is toxic in humans. Synthetic oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG) are potent adjuvants for the induction of Th1-like systemic immune responses against parenterally delivered proteins. Here, we show in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with CpG oligodeoxynucleotides and/or CT. Overall, CpG is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as mucosal immune responses (IgA) at local (lung) and distant (feces) sites. Furthermore, CpG and CT act synergistically, giving stronger responses than those observed with 10 times more of either adjuvant alone. Ab isotypes were predominantly IgG1 (Th2-like) with CT, mixed IgG1/IgG2a (Th0) with CpG, and predominantly IgG2a (Th1-like) with CpG and CT together.




This article has been cited by other articles:


Home page
Infect. Immun.Home page
E. Meoni, E. Faenzi, E. Frigimelica, L. Zedda, D. Skibinski, S. Giovinazzi, A. Bonci, R. Petracca, E. Bartolini, G. Galli, et al.
CT043, a Protective Antigen That Induces a CD4+ Th1 Response during Chlamydia trachomatis Infection in Mice and Humans
Infect. Immun., September 1, 2009; 77(9): 4168 - 4176.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Klinman, H. Shirota, D. Tross, T. Sato, and S. Klaschik
Synthetic oligonucleotides as modulators of inflammation
J. Leukoc. Biol., October 1, 2008; 84(4): 958 - 964.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
J. W. Mapletoft, M. Oumouna, J. Kovacs-Nolan, L. Latimer, G. Mutwiri, L. A. Babiuk, and S. van Drunen Littel-van den Hurk
Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection
J. Gen. Virol., January 1, 2008; 89(1): 250 - 260.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Adamsson, M. Lindblad, A. Lundqvist, D. Kelly, J. Holmgren, and A. M. Harandi
Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
J. Immunol., April 15, 2006; 176(8): 4902 - 4913.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Q. Jiang, A. Patrick, R. B. Moss, and K. L. Rosenthal
CD8+ T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligodeoxynucleotides
J. Virol., January 1, 2005; 79(1): 393 - 400.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
E. F. Pinto, R. O. Pinheiro, A. Rayol, V. Larraga, and B. Rossi-Bergmann
Intranasal Vaccination against Cutaneous Leishmaniasis with a Particulated Leishmanial Antigen or DNA Encoding LACK
Infect. Immun., August 1, 2004; 72(8): 4521 - 4527.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S.-i. Ito, K. J. Ishii, H. Shirota, and D. M. Klinman
CpG Oligodeoxynucleotides Improve the Survival of Pregnant and Fetal Mice following Listeria monocytogenes Infection
Infect. Immun., June 1, 2004; 72(6): 3543 - 3548.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. E. H. Bashir, S. Louie, H. N. Shi, and C. Nagler-Anderson
Toll-Like Receptor 4 Signaling by Intestinal Microbes Influences Susceptibility to Food Allergy
J. Immunol., June 1, 2004; 172(11): 6978 - 6987.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Coban, K. J. Ishii, A. W. Stowers, D. B. Keister, D. M. Klinman, and N. Kumar
Effect of CpG Oligodeoxynucleotides on the Immunogenicity of Pfs25, a Plasmodium falciparum Transmission-Blocking Vaccine Antigen
Infect. Immun., January 1, 2004; 72(1): 584 - 588.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. A. Prince, J. J. Mond, D. D. Porter, K. C. Yim, S. J. Lan, and D. M. Klinman
Immunoprotective Activity and Safety of a Respiratory Syncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with a CpG Oligodeoxynucleotide Adjuvant
J. Virol., December 15, 2003; 77(24): 13156 - 13160.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. N. Boyaka, A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee
Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen
J. Immunol., June 1, 2003; 170(11): 5636 - 5643.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S.-M. Kang and R. W. Compans
Enhancement of Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus
J. Virol., March 15, 2003; 77(6): 3615 - 3623.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
W. Jiang, H. J. Baker, and B. F. Smith
Mucosal Immunization with Helicobacter, CpG DNA, and Cholera Toxin Is Protective
Infect. Immun., January 1, 2003; 71(1): 40 - 46.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
L. FATTORINI, R. CRETI, R. NISINI, R. PIETROBONO, Y. FAN, A. STRINGARO, G. ARANCIA, O. SERLUPI-CRESCENZI, E. IONA, and G. OREFICI
Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against Mycobacterium avium infection
J. Med. Microbiol., December 1, 2002; 51(12): 1071 - 1079.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
Q. He, A. Mitchell, T. Morcol, and S. J. D. Bell
Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection against Herpes Simplex Virus Type 2
Clin. Vaccine Immunol., September 1, 2002; 9(5): 1021 - 1024.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
N. P. Juffermans, J. C. Leemans, S. Florquin, A. Verbon, A. H. Kolk, P. Speelman, S. J. H. van Deventer, and T. van der Poll
CpG Oligodeoxynucleotides Enhance Host Defense during Murine Tuberculosis
Infect. Immun., January 1, 2002; 70(1): 147 - 152.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. A. Horner, S. K. Datta, K. Takabayashi, I. M. Belyakov, T. Hayashi, N. Cinman, M.-D. Nguyen, J. H. Van Uden, J. A. Berzofsky, D. D. Richman, et al.
Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites
J. Immunol., August 1, 2001; 167(3): 1584 - 1591.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Shirota, K. Sano, N. Hirasawa, T. Terui, K. Ohuchi, T. Hattori, K. Shirato, and G. Tamura
Novel Roles of CpG Oligodeoxynucleotides as a Leader for the Sampling and Presentation of CpG-Tagged Antigen by Dendritic Cells
J. Immunol., July 1, 2001; 167(1): 66 - 74.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. S. Gallichan, R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L. Davis, and K. L. Rosenthal
Intranasal Immunization with CpG Oligodeoxynucleotides as an Adjuvant Dramatically Increases IgA and Protection Against Herpes Simplex Virus-2 in the Genital Tract
J. Immunol., March 1, 2001; 166(5): 3451 - 3457.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Z. Peng, H. Wang, X. Mao, K. T. HayGlass, and F. E. R. Simons
CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice
Int. Immunol., January 1, 2001; 13(1): 3 - 11.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. N. Shi, H. Y. Liu, and C. Nagler-Anderson
Enteric Infection Acts as an Adjuvant for the Response to a Model Food Antigen
J. Immunol., December 1, 2000; 165(11): 6174 - 6182.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
F. Meyer, K. T. Wilson, and S. P. James
Modulation of Innate Cytokine Responses by Products of Helicobacter pylori
Infect. Immun., November 1, 2000; 68(11): 6265 - 6272.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
W. Olszewska, C. D. Partidos, and M. W. Steward
Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants
Infect. Immun., September 1, 2000; 68(9): 4923 - 4929.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
B. L. Freidag, G. B. Melton, F. Collins, D. M. Klinman, A. Cheever, L. Stobie, W. Suen, and R. A. Seder
CpG Oligodeoxynucleotides and Interleukin-12 Improve the Efficacy of Mycobacterium bovis BCG Vaccination in Mice Challenged with M. tuberculosis
Infect. Immun., May 1, 2000; 68(5): 2948 - 2953.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
H. Shirota, K. Sano, T. Kikuchi, G. Tamura, and K. Shirato
Regulation of T-helper Type 2 Cell and Airway Eosinophilia by Transmucosal Coadministration of Antigen and Oligodeoxynucleotides Containing CpG Motifs
Am. J. Respir. Cell Mol. Biol., February 1, 2000; 22(2): 176 - 182.
[Abstract] [Full Text]


Home page
Infect. Immun.Home page
D. M. Klinman, J. Conover, and C. Coban
Repeated Administration of Synthetic Oligodeoxynucleotides Expressing CpG Motifs Provides Long-Term Protection against Bacterial Infection
Infect. Immun., November 1, 1999; 67(11): 5658 - 5663.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Wild, M. J. Grusby, R. Schirmbeck, and J. Reimann
Priming MHC-I-Restricted Cytotoxic T Lymphocyte Responses to Exogenous Hepatitis B Surface Antigen Is CD4+ T Cell Dependent
J. Immunol., August 15, 1999; 163(4): 1880 - 1887.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
R. Schirmbeck, K. Melber, and J. Reimann
Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen
Int. Immunol., July 1, 1999; 11(7): 1093 - 1102.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. L. B. Millan, R. Weeratna, A. M. Krieg, C.-A. Siegrist, and H. L. Davis
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
PNAS, December 22, 1998; 95(26): 15553 - 15558.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.